Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
Anil K. Sood, … , Steven W. Cole, Susan K. Lutgendorf
Anil K. Sood, … , Steven W. Cole, Susan K. Lutgendorf
Published April 12, 2010
Citation Information: J Clin Invest. 2010;120(5):1515-1523. https://doi.org/10.1172/JCI40802.
View: Text | PDF
Research Article Oncology

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis

  • Text
  • PDF
Abstract

Chronic stress is associated with hormonal changes that are known to affect multiple systems, including the immune and endocrine systems, but the effects of stress on cancer growth and progression are not fully understood. Here, we demonstrate that human ovarian cancer cells exposed to either norepinephrine or epinephrine exhibit lower levels of anoikis, the process by which cells enter apoptosis when separated from ECM and neighboring cells. In an orthotopic mouse model of human ovarian cancer, restraint stress and the associated increases in norepinephrine and epinephrine protected the tumor cells from anoikis and promoted their growth by activating focal adhesion kinase (FAK). These effects involved phosphorylation of FAKY397, which was itself associated with actin-dependent Src interaction with membrane-associated FAK. Importantly, in human ovarian cancer patients, behavioral states related to greater adrenergic activity were associated with higher levels of pFAKY397, which was in turn linked to substantially accelerated mortality. These data suggest that FAK modulation by stress hormones, especially norepinephrine and epinephrine, can contribute to tumor progression in patients with ovarian cancer and may point to potential new therapeutic targets for cancer management.

Authors

Anil K. Sood, Guillermo N. Armaiz-Pena, Jyotsnabaran Halder, Alpa M. Nick, Rebecca L. Stone, Wei Hu, Amy R. Carroll, Whitney A. Spannuth, Michael T. Deavers, Julie K. Allen, Liz Y. Han, Aparna A. Kamat, Mian M.K. Shahzad, Bradley W. McIntyre, Claudia M. Diaz-Montero, Nicholas B. Jennings, Yvonne G. Lin, William M. Merritt, Koen DeGeest, Pablo E. Vivas-Mejia, Gabriel Lopez-Berestein, Michael D. Schaller, Steven W. Cole, Susan K. Lutgendorf

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Total
Citations: 5 10 10 12 16 11 12 6 6 10 20 10 8 14 11 4 1 166
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2021 (16)

Title and authors Publication Year
Silencing ZIC2 abrogates tumorigenesis and anoikis resistance of non-small cell lung cancer cells by inhibiting Src/FAK signaling
A Liu, H Xie, R Li, L Ren, B Yang, L Dai, W Lu, B Liu, D Ren, X Zhang, Q Chen, Y Huang, K Shi
Molecular Therapy — Oncolytics 2021
New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management
A Cuomo, F Paudice, G DAngelo, G Perrotta, A Carannante, U Attanasio, M Iengo, F Fiore, CG Tocchetti, V Mercurio, F Pirozzi
Current Heart Failure Reports 2021
Tumor Microenvironment: Novel Concepts
A Birbrair
2021
Blood Vessels and Peripheral Nerves as Key Players in Cancer Progression and Therapy Resistance
N Roda, G Blandano, PG Pelicci
Cancers 2021
Stress Hormones: Emerging Targets in Gynecological Cancers
G Chen, L Qiu, J Gao, J Wang, J Dang, L Li, Z Jin, X Liu
Frontiers in Cell and Developmental Biology 2021
Stress and cancer: mechanisms, significance and future directions
A Eckerling, I Ricon-Becker, L Sorski, E Sandbank, S Ben-Eliyahu
Nature Reviews Cancer 2021
Cancer and Stress: Does It Make a Difference to the Patient When These Two Challenges Collide?
A Iftikhar, M Islam, S Shepherd, S Jones, I Ellis
Cancers 2021
Assessment of Epinephrine and Norepinephrine in Gastric Carcinoma
AM Mehedințeanu, V Sfredel, PO Stovicek, M Schenker, GC Târtea, O Istrătoaie, AM Ciurea, CC Vere
International journal of molecular sciences 2021
Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer
MB Hopson, S Lee, M Accordino, M Trivedi, M Maurer, KD Crew, DL Hershman, K Kalinsky
Breast Cancer Research and Treatment 2021
Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways
L Yu, M Wang, Y Yang, F Xu, X Zhang, F Xie, L Gao, X Li, J Gallo
PLoS computational biology 2021
Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells
S Dash, S Yoder, T Mesa, A Smith, L Cen, S Eschrich, GN Armaiz-Pena, AN Monteiro
Scientific Reports 2021
Chronic Stress Activates PlexinA1/VEGFR2-JAK2-STAT3 in Vascular Endothelial Cells to Promote Angiogenesis
YJ Lu, HZ Zhao, Y Liu, YZ Zuo, Q Xu, L Liu, XM Li, HB Zhu, Y Zhang, S Zhang, XY Zhao, YH Li
Frontiers in Oncology 2021
Subclinical cardiac damage in cancer patients before chemotherapy
I Fabiani, G Panichella, A Aimo, C Grigoratos, G Vergaro, NR Pugliese, S Taddei, DM Cardinale, C Passino, M Emdin, A Giannoni
Heart Failure Reviews 2021
Immunomodulatory Effects of Perioperative Dexmedetomidine in Ovarian Cancer: An In Vitro and Xenograft Mouse Model Study
S Shin, KJ Kim, HJ Hwang, S Noh, JE Oh, YC Yoo
Frontiers in Oncology 2021
Norepinephrine Enhances Aerobic Glycolysis and May Act as a Predictive Factor for Immunotherapy in Gastric Cancer
Y Wang, S Wang, Q Yang, J Li, F Yu, E Zhao, J Ji
Journal of Immunology Research 2021
LIM domain-containing 2 (LIMD2) promotes the progress of ovarian cancer via the focal adhesion signaling pathway
L Chen, J Qian, Q You, J Ma
Bioengineered 2021

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts